A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma
The combination of lenvatinib and pembrolizumab may extend by more than 1 year the lives of patients with advanced melanoma who progress after immunotherapy, show'important'trial results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Increasing the effectiveness of immunotherapy against skin cancer
(University of Bern) Researchers at the University of Bern have discovered a mechanism in the body's own immune system which is responsible for the maturation and activation of immune cells. In the fight against skin cancer, the results have the potential to help immunotherapies succeed, even in patients for whom they have so far been ineffective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 18, 2020 Category: Cancer & Oncology Source Type: news

New targets for melanoma treatment
(Monash University) A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

DNA damage caused by migrating light energy
(Karlsruher Institut f ü r Technologie (KIT)) Ultraviolet light endangers the integrity of human genetic information and may cause skin cancer. For the first time, researchers of Karlsruhe Institute of Technology (KIT) have demonstrated that DNA damage may also occur far away from the point of incidence of the radiation. They produced an artificially modeled DNA sequence in new architecture and detected DNA damage at a distance of 30 DNA building blocks. The results are reported in Angewandte Chemie (DOI: 10.1002/anie.202009216). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2020 Category: Cancer & Oncology Source Type: news

Recursion Pharmaceuticals' $239M for AI drug discovery, optimize.health's $15.6M for remote patient monitoring and more digital health fundings
Also: Skin Analytics'Series A contributes to AI-based detection of potential skin cancer; China's LickDoc supports its healthcare big data repository with $102 million. (Source: mobihealthnews)
Source: mobihealthnews - September 10, 2020 Category: Information Technology Source Type: news

DNA-based nanotechnology stimulates potent antitumor immune responses
(The Wistar Institute) Combining their expertise in protein engineering and synthetic DNA technology, Wistar scientists successfully delivered nanoparticle antitumor vaccines that stimulated robust CD8 T cell immunity and controlled melanoma growth in preclinical models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

UCLA study shows how interferon-gamma guides response to cancer immunotherapy
(University of California - Los Angeles Health Sciences) UCLA researchers shed light on how interferon-gamma (IFN-y) guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -- immune checkpoint blockade. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

New nanosystem from Tel Aviv university enhances treatment for melanoma in animal models
(American Friends of Tel Aviv University) Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro of TAU's Department of Physiology and Pharmacology at the Sackler School of Medicine, have developed an innovative nanotechnological drug delivery system that significantly enhances the effectiveness of treatment for the aggressive skin cancer melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
FRIDAY, Sept. 4, 2020 -- For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2020 Category: Pharmaceuticals Source Type: news

Durable Response: 5 Years After Adjuvant Combo in Melanoma Durable Response: 5 Years After Adjuvant Combo in Melanoma
Double targeted therapy conferred durable long-term relapse-free survival when given in the adjuvant setting in advanced melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 2, 2020 Category: Cancer & Oncology Source Type: news

How mechanical forces nudge tumors toward malignancy
(Rockefeller University) Researchers studying two forms of skin cancer identified a long-overlooked factor determining why some tumors are more likely to metastasize than others: the physical properties of the tissue in which the cancer originates. The findings might set the stage for new ways to monitor and treat the diseases in the future. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news

Effective cancer immunotherapy further linked to regulating a cell 'suicide' gene
(Johns Hopkins Medicine) Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell's natural " suicide " signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer. A summary of the research, conducted with mice and human cells, appeared Aug. 25 in Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2020 Category: Cancer & Oncology Source Type: news

Dermatology Has a Problem With Skin Color
Common conditions often manifest differently on dark skin. Yet physicians are trained mostly to diagnose them on white skin. (Source: NYT Health)
Source: NYT Health - August 30, 2020 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Skin Black People Doctors Coronavirus (2019-nCoV) Skin Cancer Race and Ethnicity Health Insurance and Managed Care Minorities Pediatric Inflammatory Multisystem Syndrome (PIMS) Textbooks Hispanic-Americans Medical Source Type: news

Risk for Cancer Reduced for Patients With Multiple Sclerosis
Pooled prevalence rates of breast cancer, digestive cancer, skin cancer were 2, 2, and 1 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 28, 2020 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Neurology, Oncology, Journal, Source Type: news

Topical Calcineurin Inhibitors Not Tied to Skin Cancer
THURSDAY, Aug. 27, 2020 -- There is no association between use of topical calcineurin inhibitors (TCIs) for the treatment of atopic dermatitis (AD) and an increased risk for skin cancer, according to a study published online Aug. 12 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Melanoma Experts Say'No' to Routine Gene Profile Testing Melanoma Experts Say'No' to Routine Gene Profile Testing
False positives, negatives too high.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 26, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Impressive Results' From Stage III Melanoma Studies: ASCO 2020'Impressive Results' From Stage III Melanoma Studies: ASCO 2020
Dr Jeffrey Weber describes three adjuvant and/or neoadjuvant studies in stage III melanoma that piqued his interest at this year's American Society of Clinical Oncology virtual meeting.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 25, 2020 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news

FDA Updates Hydrochlorothiazide Label for Nonmelanoma Skin Cancer FDA Updates Hydrochlorothiazide Label for Nonmelanoma Skin Cancer
Hydrochlorothiazide is associated with an increased risk of nonmelanoma skin cancer, according to updates to the medication's label.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 24, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

Skin cancer deaths more than DOUBLE in 50 years as British sunseekers jet abroad on cheap holidays
Official figures from Cancer Research UK reveal people are dying from melanoma skin cancer at 2.5 times the rate they were in the 1970s as more Brits jet abroad on cheap holidays. (Source: the Mail online | Health)
Source: the Mail online | Health - August 20, 2020 Category: Consumer Health News Source Type: news

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage
Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I–binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae. Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb–restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti–PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in ...
Source: ScienceNOW - August 20, 2020 Category: Science Authors: Fluckiger, A., Daillere, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., Lemaitre, F., Ferrere, G., Derosa, L., Duong, C. P. M., Messaoudene, M., Gagne, A., Joubert, P., De Sordi, L., Debarbieux, L., Simon Tags: Immunology, Medicine, Diseases r-articles Source Type: news

Better Than Ever: Beyond image, having healthy body takes on new meaning for cancer survivor
After being diagnosed with stage 2D melanoma in December 2017, fintech exec and entrepreneur Nichol Beckstrand made some changes in her life. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2020 Category: Pharmaceuticals Authors: Kim Johnson Source Type: news

Moletest offers skin cancer screening test to primary care professionals
The medical technology company aims to reduce unnecessary dermatology referrals to secondary care. (Source: mobihealthnews)
Source: mobihealthnews - August 18, 2020 Category: Information Technology Source Type: news

Skin cancer symptoms: The major warning signs that could indicate melanoma
SKIN cancer can affect almost anyone and with temperatures progressively intensifying year after year, it's never been more important to be vigilant of one's skin. What are the major warning signs of melanoma? (Source: Daily Express - Health)
Source: Daily Express - Health - August 15, 2020 Category: Consumer Health News Source Type: news

Skin cancer: How often you should apply sun cream if you want to prevent the condition
SKIN cancer is one of the most common cancers in the word, and during the summer months, a person's risk of the condition is heightened. Wearing sun cream can protect your skin, but how often should you be applying it? (Source: Daily Express - Health)
Source: Daily Express - Health - August 13, 2020 Category: Consumer Health News Source Type: news

Studying how skin cancer starts
(Case Western Reserve University) New research by Ortiz-Rodr í guez and mentor Carlos Crespo, a professor and lead researcher in the The Crespo Group lab, reveals for perhaps the first time how quickly certain pre-cancerous lesions can form on the DNA of our skin when exposed to sunlight. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2020 Category: International Medicine & Public Health Source Type: news

No increased skin cancer risk with topical immunosuppressant ointments
(Massachusetts General Hospital) Two topical immunosuppressant medications commonly prescribed to treat skin conditions do not appear to increase the risk for the most common forms of skin cancer, despite package label warnings to the contrary. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Molecules in urine allow doctors to monitor skin cancer
(De Gruyter) What if you could simply provide a urine sample rather than undergo a painful surgical procedure to find out if your cancer was responding to treatment? It may seem too good to be true, but researchers at Pavol Jozef Š af á rik University in Ko š ice, Slovakia, have identified fluorescent molecules in urine that may allow patients with malignant melanoma to do just that. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

Checking moles for cancer
Learn about moles (nevi), what causes them, whether they put you at increased risk of skin cancer and how to check a mole for signs of skin cancer. Moles are a common type of skin growth. They often appear as small, dark brown spots and are caused by clusters of pigmented cells. Moles generally appear [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 6, 2020 Category: Databases & Libraries Source Type: news

Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma Nivolumab Plus Ipilimumab or Pembrolizumab Most Cost-Effective for Newly Diagnosed Advanced Melanoma
BRAF and MEK inhibitors might be used in a second-line setting after BRAF pathogenic variant is confirmed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Boston University researcher receives grant to fight melanoma
(Boston University School of Medicine) Deborah Lang, MD, associate professor of dermatology at Boston University School of Medicine (BUSM), has been awarded a two-year, $250,000 grant from the Harry J. Lloyd Charitable Trust to further her basic science research on the molecular and cellular biology of melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2020 Category: International Medicine & Public Health Source Type: news

Skin cancer symptoms: The sign in your mouth that could signal the deadly disease
SKIN CANCER - there's a certain type of skin cancer that can be caught by an infection with a virus. The first sign of the disease appears in the mouth. Here's what to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - August 1, 2020 Category: Consumer Health News Source Type: news

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 31, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Triple Drug Combo for Melanoma FDA Approves Triple Drug Combo for Melanoma
The triple-therapy combination of atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Media News - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Investor Update - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
South San Francisco, CA -- July 30, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news

Researchers outline need for evaluation of gene expression profiling in melanoma
(Huntsman Cancer Institute) A consensus statement published today in JAMA Dermatology cautions against routine use of currently available GEP tests for patients with cutaneous melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 29, 2020 Category: Cancer & Oncology Source Type: news

Pembrolizumab Use Supported in Advanced Melanoma
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 22, 2020 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Re-treating Melanoma After PD-1 Blockade Shows Good Response Re-treating Melanoma After PD-1 Blockade Shows Good Response
In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? A recent study addresses this important question.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Pembrolizumab Use Supported in Advanced Melanoma
WEDNESDAY, July 22, 2020 -- Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 22, 2020 Category: Pharmaceuticals Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

Skin cancer treatments could be used to treat other forms of the disease
(Institut national de la recherche scientifique - INRS) The creation of a silica nanocapsule could allow treatments that use light to destroy cancerous or precancerous cells in the skin to also be used to treat other types of cancer. Such are the findings of a study by INRS (Institut national de la recherche scientifique) professors Fiorenzo Vetrone and Federico Rosei, in collaboration with an international research team. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news